
Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy. Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's lead asset is KVA12.1, a VISTA blocking immunotherapy.
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.5746 | 0.5746 | 0.5746 | 0 | 0 | CS |
4 | 0 | 0 | 0.5746 | 0.5746 | 0.5746 | 0 | 0 | CS |
12 | 0 | 0 | 0.5746 | 0.5746 | 0.5746 | 0 | 0 | CS |
26 | -0.1054 | -15.5 | 0.68 | 0.889 | 0.5599 | 9438 | 0.68694081 | CS |
52 | -0.1854 | -24.3947368421 | 0.76 | 0.889 | 0.3339 | 276368 | 0.59620685 | CS |
156 | -8.3054 | -93.5292792793 | 8.88 | 9 | 0.3339 | 144346 | 0.93033596 | CS |
260 | -8.3054 | -93.5292792793 | 8.88 | 9 | 0.3339 | 144346 | 0.93033596 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.